Abstract:Glucocerenrosidase1 (GBA1) mutations cause disruptions in endoplasmic reticulum (ER) and lysosome‐related proteostasis pathways in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons. Severe GBA1 mutations lead to increased ER stress (increased binding immunoglobulin protein (BiP) and protein disulfide isomerase (PDI) levels), total ubiquitination rates, and unfolded protein response (UPR). Defective chaperone‐mediated autophagy (decreased heat‐shock cognate protein 70 (HSC70) levels and decreased co‐localization of lysosomal‐associated membrane protein 2A (LAMP2A) and HSC70) is observed in iPSC‐derived dopaminergic neurons with mild homozygous GBA1 mutations. Decreased autophagosome formation (decreased microtubule‐associated protein light chain 3A (LC3) levels) is observed in iPSC‐derived dopaminergic neurons with homozygous N370S and D409H GBA1 mutations, while fusion defects (decreased lysosomal‐associated membrane protein 1 (LAMP1) and LC3 co‐localization) are observed in neurons with homozygous L444P GBA1 mutation. Severe GBA1 mutations trigger the accumulation of monomeric and oligomeric forms of α‐synuclein. GBA1 mutations increase the release of α‐synuclein from iPSC‐derived dopaminergic neurons. Glucocerebrosidase 1 (GBA1) mutations are the most important genetic risk factors for Parkinson's disease (PD). Clinically, mild (e.g., p.N370S) and severe (e.g., p.L444P and p.D409H) GBA1 mutations have different PD phenotypes, with differences in age at disease onset, progression, and the severity of motor and non‐motor symptoms. We hypothesize that GBA1 mutations cause the accumulation of α‐synuclein by affecting the cross‐talk between cellular protein degradation mechanisms, leading to neurodegeneration. Accordingly, we tested whether mild and severe GBA1 mutations differentially affect the degradation of α‐synuclein via the ubiquitin–proteasome system (UPS), chaperone‐mediated autophagy (CMA), and macroautophagy and differentially cause accumulation and/or release of α‐synuclein. Our results demonstrate that endoplasmic reticulum (ER) stress and total ubiquitination rates were significantly increased in cells with severe GBA1 mutations. CMA was found to be defective in induced pluripotent stem cell (iPSC)‐derived dopaminergic neurons with mild GBA1 mutations, but not in those with severe GBA1 mutations. When examining macroautophagy, we observed reduced formation of autophagosomes in cells with the N370S and D409H GBA1 mutations and impairments in autophagosome–lysosome fusion in cells with the L444P GBA1 mutation. Accordingly, severe GBA1 mutations were found to trigger the accumulation and release of oligomeric α‐synuclein in iPSC‐derived dopaminergic neurons, primarily as a result of increased ER stress and defective macroautophagy, while mild GBA1 mutations affected CMA, which is mainly responsible for the degradation of the monomeric form of α‐synuclein. Overall, our findings provide new insight into the molecular basis of the clinical variability in PD associated with different GBA1 mutations.

Effect of glucocerebrosidase inhibition on intracellular α-synuclein oligomer formation and autophagic activity of dopaminergic cells

Oligomeric Α-Synuclein Inhibits Tubulin Polymerization

Ginkgolic acid promotes autophagy-dependent clearance of intracellular alpha-synuclein aggregates

Pharmacotherapy in Parkinson’s disease: case studies

Protective effects of galantamine against Abeta-induced PC12 cell apoptosis by preventing mitochondrial dysfunction and endoplasmic reticulum stress.

Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology

Inhibition of microglial β-glucocerebrosidase hampers the microglia-mediated antioxidant and protective response in neurons

Stimulation of autophagy prevents amyloid-β peptide-induced neuritic degeneration in PC12 cells.

AAV delivery of GBA1 suppresses alpha-synuclein accumulation in Parkinson's disease models and restores motor dysfunction in a Gaucher's disease model

Variant‐specific effects of GBA1 mutations on dopaminergic neuron proteostasis

Protective Effects of Ambroxol on Aβ and α-Synuclein-Induced Neurotoxicity Through Glucocerebrosidase Activation in HT-22 Hippocampal Neuronal Cells

Insight into the Effect of Methylglyoxal on the Conformation, Function, and Aggregation Propensity of α‐Synuclein

Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson’s disease

Ginkgolide K Promotes the Clearance of A53T Mutation Alpha-Synuclein in SH-SY5Y Cells

Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease

In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

synuclein-induced toxicity

Gingko Biloba Extract (egb) Inhibits Oxidative Stress in Neuro 2A Cells Overexpressing APPsw

Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons

The GBA1 K198E Variant Is Associated with Suppression of Glucocerebrosidase Activity, Autophagy Impairment, Oxidative Stress, Mitochondrial Damage, and Apoptosis in Skin Fibroblasts

Inhibition of neuronal mitochondrial complex I or lysosomal glucocerebrosidase is associated with increased dopamine and serotonin turnover